We previously identified CD34-negative (CD34 − ) severe combined immunodeficiency (SCID)-repopulating cells as primitive hematopoietic stem cells (HSCs) in human cord blood. In this study, we develop a prospective ultra-high-resolution purification method by applying two positive markers, CD133 and GPI-80. Using this method, we succeed in purifying single long-term repopulating CD34 − HSCs with self-renewing capability residing at the apex of the human HSC hierarchy from cord blood, as evidenced by a single-cell-initiated serial transplantation analysis. The gene expression profiles of individual CD34 + and CD34 − HSCs and a global gene expression analysis demonstrate the unique molecular signature of CD34 − HSCs. We find that the purified CD34 − HSCs show a potent megakaryocyte/erythrocyte differentiation potential in vitro and in vivo. Megakaryocyte/erythrocyte progenitors may thus be generated directly via a bypass route from the CD34 − HSCs. Based on these data, we propose a revised road map for the commitment of human CD34 − HSCs in cord blood.
H ematopoietic stem cells (HSCs) are a self-renewing population with the developmental potential to give rise to all types of mature blood cells [1] [2] [3] . It is well-documented that HSCs possess enormous therapeutic potential in the context of hematopoietic stem cell transplantation (HSCT) and regenerative medicine [4] [5] [6] [7] . Recent advances in fluorescence-activated cell sorting (FACS) technology have enabled prospective isolation of murine HSCs to high purity using various cell surface markers, including CD34, Sca-1 and the SLAM family receptors 8, 9 . Among them, the CD34 antigen has long been believed to be a reliable HSC marker in mammals 10 . Two decades ago, Nakauchi et al., however, challenged this long-standing dogma, showing that murine long-term (LT) lympho-myeloid reconstituting HSCs (LT-HSCs) are lineage negative (Lin − ), c-kit-positive (c-kit + ), Sca-1-positive (Sca-1 + ) and CD34 − low/negative (CD34 low/− ) (CD34 low/− KSL) cells 11 . Furthermore, individual purified CD34 low/− KSL cells were able to fully reconstitute lymphomyeloid hematopoiesis in recipient mice.
In contrast, the purification and isolation of bona fide human CD34 − HSCs has lagged far behind the abovementioned murine CD34 low/− KSL cells 11 . However, a number of studies have suggested that human bone marrow (BM)-derived and cord blood (CB)-derived CD34 low/− cell populations contain LT-HSCs [12] [13] [14] . Dick et al. developed a SCID-repopulating cell (SRC) assay to measure primitive human HSCs in a xenotransplantation setting with NOD/SCID mice 15, 16 . Using this system, Bhatia et al. first reported that SRCs are present in human BM-derived and CBderived Lin − CD34 − cells 17 . However, the incidence of SRCs in Lin − CD34 − cells was reportedly very low (1/125,000).
We previously identified very primitive CD34 − SRCs in human CB using the intra-bone marrow injection (IBMI) method 18 and proposed a new concept for the hierarchy in the human HSC compartment 19, 20 . However, the incidence of CD34 − SRC in 13 Lin − CD34 − cells (1/25,000) was still low 18 . We then developed a high-resolution purification method capable of enriching CD34 − SRCs at a 1/1000 level in an 18Lin − CD34 − fraction 21 . In addition, we further identified CD133 as a positive marker for CD34 − as well as CD34 + SRCs 22 , which can enrich CD34 + and CD34 − SRCs at approximately 1/100 and 1/140 in 18Lin − CD34 +/− CD133 + fractions, respectively 20, 22 . Very recently, we demonstrated that the glycosylphosphatidylinositol-anchored protein GPI-80, which was originally reported to regulate neutrophil adherence and migration 23, 24 , was also expressed on human full-term CB-derived 18Lin − CD34 + CD38 − and 18Lin − CD34 − cells 25 . Interestingly, CB-derived CD34 − SRCs were highly enriched in the 18Lin − CD34 − GPI-80 + cell fraction at the 1/20 level 25 .
In this study, we combine two positive/enrichment markers, CD133 and GPI-80, in order to achieve ultra-high purification of CD34 + and CD34 − HSCs and successfully purify both SRCs at 1/5 and 1/8 cell levels, each of which turns out to be the highest purification levels to date. We then explore the biological nature of human CB-derived CD34 + and CD34 − SRCs (HSCs) to clarify the difference in their stem cell nature using single-cell-based in vivo transplantation and gene expression analyses. These detailed single-cell-based analyses allow us to distinguish human CB-derived CD34 + and CD34 − HSCs and map CD34 − HSCs at the apex of the human HSC hierarchy.
Results
Development of an ultra-high-resolution purification method. Using two positive markers CD133 22 and GPI-80 25 , we developed an ultra-high-resolution purification method for isolating CD34 + and CD34 − HSCs at the single-cell level (Fig. 1a-f) . The 18Lin − CD34 + CD38 − CD133 + GPI-80 +/− (R6 and R7) (abbreviated as (Fig. 1h) .
In a separate set of experiment, we analyzed the expression patterns of CD90, CD49f, CD93 and CXCR4 on the surfaces of 18Lin − CD34 + CD38 − CD133 + GPI-80 + (R6) and 18Lin − CD34 − CD133 + GPI-80 + (R8) cells using seven single-CB units. As shown in Supplementary Fig. 1 (Fig. 1j) , whereas the 34 + 38 − 133 + 80 +/− cells mainly formed CFU-Mix colonies (73 and 61%). These results indicated that CFCs of human CB-derived CD34 + and CD34 − HSCs are clearly different, and CD34 − HSCs had a potent megakaryocyte/erythrocyte differentiation potential in vitro. Representative colonies and their constituent cells are shown in Supplementary Fig. 2 .
Cell cycle status of CD34 + and CD34 − HSCs. Most murine adult BM-derived HSCs are known to be cell cycle dormant 26 . However, murine fetal HSCs derived from the AGM (aortagonad-mesonephros), placenta and fetal liver are largely cycling 26 . In contrast to extensive studies on murine HSCs, the cell cycle status of human primitive HSCs has not been fully elucidated. Human BM-derived CD34 + CD38 − cells containing primitive LT-HSCs have been reported to be cell cycle dormant 27, 28 . However, the cell cycle status of human CB-derived primitive HSCs remains unclear. Therefore, it is necessary to validate the reported findings of murine HSCs in the human HSC hierarchy. In such efforts, it is critical to use a highly purified human HSC population for investigating the cell cycle status/ dormancy, as contamination with committed progenitors in the HSC population would hamper the accurate determination of the cell cycle status. As shown in this study, 34 + 38 − 133 + 80 + and 34 − 133 + 80 + cells, which showed high incidences of CD34 + and CD34 − SRCs (HSCs), provided robust multi-lineage human cell repopulation at 20 weeks after transplantation and efficient engraftment upon the secondary transplantation.
We therefore investigated the proportions of CD34 + and CD34 − SRCs (HSCs) in each cell cycle phase using the abovementioned 34 + 38 − 133 + 80 +/− (R6 and R7 in Fig. 1e ) and 34 − 133 + 80 +/− (R8 and R9 in Fig. 1f ) cells via the Ki-67/7-AAD staining method. As shown in Supplementary Fig. 3a, approximately 30 Fig. 3c -e). The purification methods of these target cells are shown in Supplementary Fig. 3c . As shown in Supplementary  Figs. 3d and e, the proportions of CB-derived CD34 + HSC/HPCs in the G 0 phase was <40%. The proportion of cells in the G 0 phase gradually decreased in accordance with the differentiation status ( Supplementary Fig. 3d and e). In contrast, the proportion of BMderived CD90 + HSCs in the G 0 phase was >90% ( Supplementary  Figs. 3d and e) . And the proportions of MPPs, MLPs and CD34 + CD38 high HPCs in the G 0 phase were about 80, 70 and 30%, respectively. The cell cycle status of BM-derived CD34 + HSCs was consistent with the findings of the previous reports 27, 28 . However, the cell cycle status of the CB-derived CD34 + and CD34 − HSCs in the present study was different from the previously reported data 29 . The CB-derived CD34 + and CD34 − SRCs (HSCs) seemed to be in a greater cycling flux than previously estimated 29 . This is not very surprising, as CB-derived primitive CD34 + and CD34 − HSCs may reflect fetal hematopoiesis [30] [31] [32] .
In order to validate the dormancy of CB-derived CD34 + and CD34 − SRCs (HSCs), we performed a single-cell proliferation assay. As shown in Supplementary Fig. 4a , single 34 + 38 − 133 + 80 + and 34 − 133 + 80 + cells began to divide after 48 h of culture with basal medium containing SCF + TPO. Half of these cells completed their first cell division by 96 h of culture. In contrast, almost all of the 18Lin − CD34 + CD38 high cells completed their first cell division by 48 h of culture. In the culture with complete medium containing 10% FCS and 7 cytokines (SCF, TPO, FL, IL-3, IL-6, GM-CSF and G-CSF), almost all of the three classes of HSCs/HPCs completed their first cell division by 96 h of culture ( Supplementary Fig. 4b ). Among the three classes of HSCs/HPCs, the CD34 + CD38 high cells (HPCs) most rapidly proliferated, and the 34 − 133 + 80 + cells (CD34 − HSCs) most slowly proliferated. We then determined how long it took for these three classes of HSCs/HPCs to complete the first cell division (time to complete first cell division, T fcd ) ( Supplementary Fig. 4c ). The T fcd of both the 34 + 38 − 133 + 80 + and 34 − 133 + 80 + cells were approximately 70 h in the basal medium. This was significantly longer than the T fcd (40 h) of the 18Lin − CD34 + CD38 high cells. The T fcd of the two classes of HSCs was significantly shorter in the complete medium than in the basal medium. Interestingly, the time to complete second cell division (T scd ) of all 3 classes of HSCs/HPCs ranged from 20 to 30 h, regardless of the culture media ( Supplementary Fig. 4d ). These results suggest that both primitive CD34 + and CD34 − HSCs and committed HPCs begin to divide in the same fashion once they start their proliferation in cultures.
Combination of CD133 and GPI-80 for purification of HSCs. We performed a limiting dilution analysis (LDA) to determine the frequencies of CD34 + and CD34 − SRCs in the abovementioned four-cell fractions (R6 to R9 in Fig. 1 Fig. 2a; Supplementary  Data 2a) . All of the primary recipient mice showed signs of human cell repopulation at 12 weeks after transplantation. The repopulation levels were maintained until 20 to 22 weeks after transplantation (Fig. 2b) . Both the CD34 + and CD34 − SRCs showed multi-lineage reconstitution abilities in the BM, peripheral blood (PB), spleen and thymus ( Fig. 2d, e; Supplementary  Data 2b) .
We then performed secondary transplantation. Most of the secondary recipient NOG mice that received 1/5 of whole BM cells from the primary engrafted recipient mice showed distinct multi-lineage reconstitution (Fig. 2c , Supplementary Data 2a and 2c and Supplementary Fig. 6 18 . In contrast, in the case of CD34 − SRCs, 6 out of 10 mice that received resorted 18Lin − CD34 + cells showed multi-lineage human cell repopulation. These results clearly indicated that CD34 − SRCs were able to generate CD34 + SRCs in vivo, as we reported previously 18, 33 . Very interestingly, 4 out of 10 mice that received 18Lin − CD34 − cells resorted from primary recipient mice that received 34 − 133 + 80 + cells showed multi-lineage human cell reconstitution ( Supplementary Fig. 7 ). These observations suggest that CD34 − SRCs were able to self-renew in NOG mice.
Lineage differentiation potential of HSCs in vivo. Next, we precisely analyzed the multi-lineage differentiation potentials of CD34 + and CD34 − SRCs in various organs, including the BM, PB, spleen and thymus, in the abovementioned primary recipient NOG mice that received 200 34 + 38 − 133 + 80 + or 34 − 133 + 80 + cells (Supplementary Data 2b). As shown in Supplementary  Fig. 8a , the human CD45 + cell repopulation capacities of both CD34 + and CD34 − SRCs were not statistically different. These data were consistent with our previously reported data 18, 21, 22, 25, 33 . However, the differentiation potentials of these CD34 + and CD34 − SRCs with regard to CD19 + lymphoid cells were clearly different. These CD34 + SRCs showed repopulation of CD19 + cells at significantly higher levels than CD34 − SRCs in the left tibia (injected site) and PB ( Supplementary Fig. 8a(iv) ), which is consistent with our previous report 34 . Very interestingly, these CD34 − SRCs showed significantly higher levels of CD41 + cells than CD34 + SRCs in the left tibia (injected site) and spleen ( Supplementary Fig. 8a(vi) ). Furthermore, these CD34 − SRCs also showed significantly higher levels of CD235a + cells than CD34 + SRCs in the left tibia (injected site) and other bones ( Supplementary Fig. 8a(vii) ). These results demonstrated that CD34 − SRCs (HSCs) possess more potent megakaryocyte/ erythrocyte differentiation potential in vivo than CD34 + SRCs (HSCs).
We then precisely analyzed the multi-lineage differentiation potentials of CD34 + and CD34 − SRCs in secondary transplantations (Supplementary Data 2c highly repopulated with human CD45 + cells. The human CD45 + cell repopulation rates of the mice that were transplanted with CD34 + SRCs at 12 and 18 weeks after transplantation were significantly higher than those of the mice that were transplanted with CD34 − SRCs. However, the repopulation rates of both mice were comparable at 20 to 22 weeks after transplantation (mean ± S.D., *p < 0.05, **p < 0.01, two-tailed Student's t-test). c The kinetics of human CD45 + cell reconstitution in secondary recipient NOG mice that received 1/5 of whole BM cells from the abovementioned primary recipient mice. The repopulation rates of both mice (n = 17 for CD34 + SRCs and n = 15 for CD34 − SRCs) were comparable during the observation period (12 to 23 weeks after transplantation) (there were no significant differences between both group, two-tailed Student's t-test). , the human CD45 + cell repopulation capacities of CD34 + and CD34 − SRCs were not statistically different. These CD34 − SRCs, however, showed significantly higher levels of CD34 + cells than CD34 + SRCs in the both tibiae (injected site) and other bone ( Supplementary Fig. 8b (ii)). These results suggest that CD34 − SRCs are a more immature class of HSCs than CD34 + SRCs. Analyses of the BM (other bones), PB and spleens of the two representative mice that received either CD34 + SRC a or CD34 − SRC b revealed that both SRCs had an in vivo differentiation capacity comparable to that of CD34 + stem/progenitor cells, CD19 + B-lymphoids, CD33 + /CD11b + myeloids, CD14 + monocytes, CD235a + erythroid and CD41 + megakaryocytic lineages. CD56 + NK cells were detected in the spleen. These results confirmed that both CD34 + and CD34 − SRCs had definite multi-lineage differentiation potential.
Detailed FCM data of all recipient mice that received single CD34 + and CD34 − SRCs are presented in Supplementary Data 3b all four single CD34 − SRC-engrafted mice (CD34 − NSG 027, 058, 076 and 079) repopulated each of the two secondary recipient NSG mice (eight mice in total) (Supplementary Data 3a). All eight secondary recipient NSG mice showed distinct multilineage human cell repopulation by 12 to 22 weeks after transplantation (Supplementary Data 3c). The repopulation patterns of one representative NSG mouse (34 − NSG058) are shown in Supplementary Fig. 9a and c. It was quite interesting that the patterns of the multi-lineage repopulation observed in the two secondary recipient mice were not equivalent, suggesting that daughter SRCs generated from the single parental CD34 + and CD34 − SRCs were functionally heterogeneous. Finally, we performed tertiary transplantation with whole BM cells from secondarily engrafted recipient mice that originally received single purified CD34 + and CD34 − SRCs (Supplementary Data 3a). Two secondary recipient NSG mice (34 + NSG046a and NSG046b) that originally received a single 34 + 38 − 133 + 80 + cell in primary transplantation engrafted 2/4 tertiary recipient mice 22 weeks after transplantation ( Supplementary Fig. 9d ). Of note, two secondary recipient NSG mice (34 − NSG058a and NSG058b) that originally received a single 34 − 133 + 80 + cell in primary transplantation did engraft 4/4 tertiary recipient mice ( Supplementary Fig. 9d ). All of the tertiary engrafted mice showed multi-lineage human CD45 + cell repopulation at 22 weeks after transplantation ( Supplementary Fig. 9d and Supplementary Data 3d). These results clearly demonstrated that human CB-derived single purified CD34 + and CD34 − SRCs can extensively self-renew in xenografted mice.
CD34 − HSCs reside at the apex of the human HSC hierarchy. As we reported previously, CD34 − SRCs (HSCs) are able to generate CD34 + SRCs (HSCs) in vitro 25, 35, 36 and in vivo. 18, 33 In this study, we showed that CD34 − SRCs (HSCs) (18Lin − CD34 − CD133 + GPI-80 + cells) were able to generate CD34 + as well as CD34 − SRCs (HSCs) in vivo ( Supplementary Fig. 7e and f) . However, CD34 + SRCs (HSCs) (18Lin − CD34 + CD38 − CD133 + GPI-80 + cells) were only able to generate CD34 + SRCs (HSCs) in vivo ( Supplementary Figs. 7b and c). They were unable to generate CD34 − SRCs (HSCs) in vivo. To elucidate the hierarchical position of the CD34 − SRCs (HSCs) (18Lin − CD34 − CD133 + GPI-80 + cells) in comparison to previously wellestablished CD34 + SRCs (HSCs) (9Lin − CD34 + CD38 − CD45RA − CD90 + CD49f + cells) 3 , we next co-cultured CB-derived 18Lin − CD34 − CD133 + GPI-80 + and 9Lin − CD34 + CD38 − CD45RA − CD90 + CD49f + cells with human BM-derived CD271 + SSEA-4 + MSCs (DP MSCs) 35 . The results are shown in Supplementary  Fig. 10 and Supplementary Data 4. The 18Lin − CD34 − CD133 + GPI-80 + cells were able to generate 9Lin − CD34 + CD38 − CD45RA − CD90 + CD49f +/− cells with SRC activities (Supplementary Fig. 10i and j) . Furthermore, they were able to generate CD34 − SRCs (HSCs) in vitro ( Supplementary Fig. 10k ). These results are consistent with the findings of the in vivo study, as shown in Supplementary Fig. 7 . In contrast, the 9Lin − CD34 + CD38 − CD45RA − CD90 + CD49f + cells were able to generate CD34 + CD38 − CD45RA − CD90 + CD49f +/− cells with SRC activities ( Supplementary Fig. 10d and e) . However, they were unable to generate CD34 − SRCs (HSCs) in vitro ( Supplementary  Fig. 10f ). These results suggest that CD34 − SRCs (HSCs) (18Lin − CD34 − CD133 + GPI-80 + cells) are more immature than CD34 + SRCs (HSCs) (9Lin − CD34 + CD38 − CD45RA − CD90 + CD49f + cells) in the human HSC hierarchy, indicating that CD34 − SRCs (HSCs) reside at the apex of the human HSC hierarchy.
A unique molecular signature of CD34 − HSCs. To provide an independent line of evidence for characterizing our highly purified CD34 + and CD34 − SRCs (HSCs), we analyzed the gene expression profiles of these two classes of SRCs (HSCs) and other types of progenitors and mature cells at the single-cell level. As shown in Fig. 4a , a principal component analysis (PCA) demonstrated that the gene expression profiles of individual CD34 − HSCs were clearly different from those of CD34 + and CD90 + HSCs 3 . In contrast, the gene expression profiles of individual CD34 + and CD90 + HSCs overlapped. An unsupervised hierarchical clustering analysis (Fig. 4b) clearly showed two clusters; 1 and 2. Interestingly, all CD34 − HSCs belonged to cluster 1. Conversely, cluster 2 contained some of CD34 + HSCs, CD90 + HSCs and various HPCs, including multipotent progenitors (MPPs), common myeloid progenitors (CMPs), granulocyte/macrophage progenitors (GMPs), megakaryocyte/ erythrocyte progenitors (MEPs) and multilymphoid progenitors (MLPs). These results demonstrated that the gene expression profiles of CD34 − HSC were unique and largely different from those of other classes of CD34 + HSCs. We then performed a heatmap analysis, as shown in Fig. 4c . We identified three independent clusters that respectively contained HSC/HPC-related (A), HPC-related (B) and mature cell-related (C) genes.
We next focused on the gene expression profiles of primitive CD34 + and CD34 − and CD90 + HSCs in the heatmap (Fig. 5a ). These three classes of primitive HSCs showed different gene expression profiles. As shown in the upper column of violin plots (Fig. 5b) , HSC maintenance genes such as the KIT, RUNX1, TAL1, BMI1, DNMT3A and TGFBR1 and R2 were comparably expressed in these three classes of HSCs. In contrast, genes such as the IFITM1, MPL, IKZF1, ETV6, ALDH1A1 and IGF1R were more highly expressed in CD34 + and/or CD90 + HSCs than in CD34 − HSCs (Fig. 5b) . Very characteristically, the EZH2 and MYB genes were turned out to be highly expressed in CD34 − HSCs (Fig. 5b) . Overall, the PCA and unsupervised hierarchical clustering analyses demonstrated that the gene expression profiles of individual CD34 + and CD34 − HSCs were clearly different.
Global gene expression analyses of CD34 + and CD34 − HSCs. Finally, we performed global gene expression analyses of highly purified human CB-derived 18Lin − CD34 + CD38 − CD133 + GPI-80 + cells (referred to as CD34 + HSCs) and 18Lin − CD34 − CD133 + GPI-80 + cells (referred to as CD34 − HSCs). As a control, we sorted 18Lin − CD34 + CD133 − cells (referred to as non-SRCs [non-HSCs]), that had an undetectable level of SRC activity, as previously reported 22 .
First, we compared the gene expression profiles of CD34 + and CD34 − HSCs using a gene set enrichment analysis (GSEA). Gene sets enriched in CD34 + HSCs are those related to interferon α/β/ γ response/signaling, cell adhesion/migration, cytokine signaling in the immune and inflammatory responses (Fig. 6a right) . Gene sets enriched in CD34 − HSCs are those related to hypoxia, ontogeny, megakaryocyte/erythrocyte differentiation, Wnt signaling and angiogenesis (Fig. 6a left) . As described above, the CD34 − HSCs showed potent megakaryocyte/erythrocyte differentiation potential in vitro and in vivo. It is interesting that the gene set related to megakaryocyte/erythrocyte differentiation was enriched in CD34 − HSCs.
We then focused on the signaling pathways important for the HSC function and maintenance. Interestingly, CD34 − HSCs expressed higher levels of the gene set related to Wnt signaling (Fig. 6a, b) , while CD34 + HSCs expressed higher level of the gene sets related to IFN-α, IFN-γ, TGF-β and Notch signaling (Fig. 6a,  c) . As mentioned above, a single-cell gene expression analysis clearly showed that CD34 − HSCs expressed lower levels of IFITM1 than CD34 + HSCs (Fig. 5b) . Therefore, we next analyzed the IFN-related signaling genes. As shown in Supplementary Hierarchical clustering analysis: dendrogram   KIT  CD34  PROM1  RUNX1  FLI1  FLT3  BMI1  BCL11A  DNMT3A  TGFBR1  SMAD3  TAL1  MLLT3  AFF1  IGF1R  BMPR2  LMO2  HOXA9  KLF3  TFRC  GMNN  GFI1  EZH1  SMAD2  EZH2  XBP1  RING1  ALDH1A1  TCF7  MLLT1  IL6ST  CXCR4  VPREB3  FOXO3  SMAD4  SUZ12  MYB  NFE2  NOTCH1  SMAD5  DNMT1  EED  MPL  GFI1B  IKZF1  IFITM1  CSF2RA  IL6R  NOTCH2  CSF1R  IGF2R  IL3RA  TGFBR2  RBPJ  CTNNB1  NFE2L2  ETV6  KLF13  ACTB  GAPDH  PGK1 37, 38 . These results therefore suggest that CD34 − HSCs may be more resistant than CD34 + HSCs to chronic activation of the IFN-α pathway.
Next, we compared the gene expression profiles of CD34 + and CD34 − SRCs (HSCs) with those of non-SRCs (non-HSCs) by a GSEA. The results showed that gene sets related to quiescence, inflammatory signaling, HSC markers, cell adhesion, cytokine signaling and chemokine/migration were enriched in CD34 + and CD34 − SRCs (HSCs) ( Supplementary Fig. 12a right) Reference genes TGFBR1  TGFBR2  PROM1  CD34  AFF1  IGF1R  TAL1  FLT3  MYB  CXCR4  MPL  LMO2  MLLT3  HOXB4  HOXA9  GFI1B  ALDH1A1  IFITM1  KLF10  GATA2  FLI1  KLF3  TFRC  GATA1  KLF13  NFE2L2  NFE2  CD109  IL6ST  FOXO3  IL6R  CSF2RA  GFI1  IL3RA  SPI1  CSF1R  CEBPA  BCL11A  XBP1  IKZF1  GATA3  VPREB3  TCF7  BMI1  SUZ12  DNMT3A  EZH2  ETV6  EED  DNMT1  RING1  CBX6  CBX4 non-SRCs (non-HSCs) ( Supplementary Fig. 12a left) . We then selected the 1323 differentially expressed probes with a >twofold difference in expression between CD34 + and CD34 − SRCs and non-SRCs ( Supplementary Fig. 12b) . A heatmap analysis identified several marker molecules previously reported for characterizing/purifying human HSCs, including ITGA6, PROCR, endothelial cell-selected adhesion molecule (ESAM) and PROM1 (CD133). CD34 + and CD34 − SRCs (HSCs) expressed higher levels of ITGA6 (CD49f) than non-SRCs, which was consistent with a recent report that CD49f was a specific HSC marker for human CB-derived CD90 + HSCs 3 . Interestingly, CD34 + and CD34 − SRCs (HSCs) expressed higher levels of PROCR (EPCR) than non-SRCs. As recently reported 39 , EPCR/PAR1 signaling facilitated LT-HSC BM repopulation, retention and the survival. Very recently, Yokota et al. reported that ESAM was a useful purification marker for human BM and CB-derived HSCs 40 . As expected from our ultra-high-resolution purification method, CD34 + and CD34 − SRCs (HSCs) expressed higher levels of PROM1 (CD133) than non-SRCs. In contrast, non-SRCs expressed higher levels of the CD93 gene, which was reported to be a positive marker for human CB-derived CD34 − HSCs 41 . However, as shown in Supplementary Fig. 1 [42] [43] [44] Thus, CB is now one of the most commonly used sources for allogeneic hematopoietic stem cell transplantation (HSCT). [42] [43] [44] However, the number of HSCs residing in CB units is limited resulting in delayed neutrophil and platelet recovery and engraftment failure. Both are life-threatening complications.
To overcome these clinical challenges, efficient ex vivo expansion of CB-derived HSCs is awaited. The purine derivative StemRegenin-1 (SR-1) was first identified to promote the expansion of CD34 + HSCs/HPCs. 45 Cultures of CB-derived CD34 + cells in the presence of SCF + TPO + FL + SR-1 led to a 50-fold increase in CD34 + cells and a 17-fold increase in SRCs. Recently, a pyrimidoindole derivative (UM171) was found to attenuate cell differentiation and promoted the ex vivo expansion of CB-derived CD34 + CD45RA − cells. 46 Interestingly, the frequencies of LT-HSCs were 13-fold higher in cultures supplemented with UM171 than in those supplemented with DMSO control. Given these findings, we tried to expand very primitive CB-derived CD34 − SRCs (HSCs) (18Lin − CD34 − CD133 + GPI-80 + cells) using SCF + TPO + FL + SR-1 or UM171. As shown in Supplementary Fig. 13c and d, 18Lin − CD34 − CD133 + GPI-80 + cells actively proliferated and showed 460-fold (UM171) to 950-fold (SR-1) increases in total numbers of cells, yielding 9 × 10 5 (UM171) to 13 × 10 5 (SR-1) 12Lin − CD45RA − CD34 + cells. We then performed LDAs to analyze their effects on the expansion of SRCs ( Supplementary Fig. 13e and f). Unfortunately, we were unable to expand CD34 − SRCs (HSCs). As shown in this study ( Supplementary Figs. 7 and 10 ), CD34 − SRCs (HSCs) did generate CD34 + SRCs (HSCs) in these cultures in the presence of cytokines plus SR-1 or UM171 ( Supplementary Fig. 13a and b) . However, the expansion efficiencies were 1.33 for SR-1 and 0.42 for UM171 (Supplementary Fig. 13a and f) . These efficiencies were not statistically significant in comparison to DMSO (control). These results showed that the ex vivo expansion of primitive CB-derived CD34 − SRCs (HSCs) was more difficult than previously considered, and suggesting that ex vivo expansion of primitive CB-derived CD34 − SRCs (HSCs) may require niche cells/factors for maintenance and/or proliferation. Further studies will be needed to clarify the details of this important issue.
Discussion
We developed an ultra-high-resolution purification method using two positive markers, CD133 and GPI-80, and succeeded in highly purifying human CB-derived CD34 + and CD34 − SRCs (HSCs) at 1/5 and 1/8 cell levels, respectively. GPI-80 has recently been reported as a positive marker for human fetal liver hematopoietic stem/progenitor cells (HSPCs) 47 . Because human placenta/CB-derived HSPCs reflect fetal hematopoiesis 30, 31 , it is conceivable that GPI-80 is expressed on CB-derived primitive HSCs. Interestingly, both CD133 and GPI-80 were correlated with the polarization and migration of leukocytes and HSPCs 23, 24, 48, 49 . Thus, these two molecules seem to be functional markers. Our updated method enables us to perform single-cellbased transplantation analyses. Supplementary  Fig. 9a to c) . Furthermore, both CD34 + and CD34 − SRCs showed substantial single-cell-initiated tertiary repopulating capacities (Supplementary Data 3a and Supplementary Fig. 9d ). This indicates that both SRCs sustained human multi-lineage hematopoiesis in NSG mice for over one year (Supplementary Data 3a) . These results showed that individual CD34 + and CD34 − SRCs (HSCs) have potent proliferative and extensively self-renewing capacities.
In this study, the single-cell transplantation efficiencies of highly purified 34 + 38 − 133 + 80 + and 34 − 133 + 80 + cells were 11 and 6%, respectively (Supplementary Data 3a), which were still relatively low. The xenotransplantation assay with NOG/NSG mice for detecting SRC activity, however, is not an ideal assay system, partly because of its species specificity 50 . As we showed in the present study, single CD34 + and CD34 − SRCs exerted robust Single-cell-based gene expression analyses, such as the PCA analysis and unsupervised hierarchical clustering analysis, demonstrated that gene expression profiles of individual CD34 + and CD34 − HSCs were clearly different (Fig. 4a, b) . However, immunophenotypically homogeneous CD34 − (18Lin − CD34 − CD133 + GPI-80 + ) and CD34 + (18Lin − CD34 + CD38 − CD133 + GPI-80 + ) HSCs are still very heterogeneous from the point of gene expression. These findings may reflect the variable hematopoietic repopulation patterns of individual CD34 − and CD34 + SRCs (HSCs) observed in the BM, PB and spleen (Supplementary Data 3a to c). As shown in Fig. 5b , individual CD34 − HSCs showed unique gene expression profiles, including for the IFITM1, MPL, IKZF1, ETV6, ALDH1A1, IGF1R, EZH2 and MYB genes, in comparison to CD34 + HSCs. Furthermore, GSEAs also demonstrated clear differences between these two classes of CD34 + and CD34 − HSCs (Fig. 6 ). Among them, we focused on the expression of IFITM1. The expression of IFITM1 in individual CD34 − HSCs was extremely low in comparison to CD34 + HSCs (Fig. 5b) . In addition, the GSEA demonstrated that gene sets related to IFN-α/β/γ response/signaling are enriched in CD34 + HSCs. As expected, genes related to IFN signaling, including STAT1, IFITM1, IFITM3, DDX58, IFI44, CXCL10 and CXCL11, showed significantly higher expression in CD34 + HSCs than in CD34 − HSCs (Supplementary Fig. 11 ). It is welldocumented that type I IFNs are essential for establishing the host antiviral state. However, their roles in human steady-state hematopoiesis have not been elucidated. Our present data suggest that CD34 − HSCs may be more resistant than CD34 + HSCs to chronic activation of the IFN-α pathway. This suggests that CD34 − HSCs may be able to keep their dormancy and survive under the emerging condition. Taken together, these results suggest that independent molecular backgrounds control selfrenewal, maintenance and epigenetic regulation in these two classes of CD34 + and CD34 − HSCs. The application of the current ultra-high-resolution purification method may provide a clue for uncovering fundamental molecular mechanisms that control human CB-derived CD34 + and CD34 − HSCs.
Over the past two decades, the road map of murine HSC differentiation has been reevaluated due to the accumulation of new findings in this field [51] [52] [53] . However, that of humans has remained relatively unchanged. Under the current model 1 (Fig. 7a) , the immunophenotype of LT-HSC is Lin − CD34 + CD38 − CD45RA − CD90 + CD49f +3 . These LT-HSCs give rise to MPPs, MLPs, CMPs, GMPs and MEPs 1-3 which are basically close to the mouse model. The findings concerning HSC biology obtained in mice cannot, however, always be extrapolated to humans. Therefore, it is necessary to perform validation studies using human HSCs. Doulatov et al. reported a revised road map for the human HPC hierarchy 2 . They showed that monocytes/macrophages and dendritic cells arise in early lymphoid specification. As very recently reported by Notta et al., human fetal liver contained oligopotent progenitors, while few oligopotent progenitors were present in adult BM that was proposed by the precise analysis of single purified CD34 + HSCs 54 .
In the present study, we analyzed the lineage potentials of highly purified human CB-derived CD34 + and CD34 − HSCs in vitro as well as in vivo. Single-purified CD34 + HSCs mainly formed CFU-Mix colonies in addition to CFU-GM and BFU-E. In contrast, single-purified CD34 − HSCs mainly formed CFU-EM colonies. Unexpectedly, 90% of the colonies formed by 34 − 133 + 80 − cells were CFU-EM (Fig. 1j) . When we transplanted CD34 − HSCs into NOG/NSG mice, they were able to produce CD34 + HSCs in vivo, as previously reported 18, 33 and gave rise to all types of hematopoietic cells (Figs. 2 and 3 ). When we cocultured CD34 − HSCs with DP MSCs 35 in the presence of a cocktail of cytokines, they produced CD34 + HSCs in vitro ( Supplementary Fig. 10 and Supplementary Data 4) as previously reported 25, 35, 36 . After co-culturing, the recovered cells were recultured in methylcellulose to confirm their lineage potentials, and all types of CFCs, including CFU-GM, BFU-E and CFU-Mix, were detected 35 . These results suggest that CD34 − HSCs can generate CD34 + HSCs in the presence of DP MSCs (niche cells) and give rise to all types of hematopoietic progenitor cells, as observed in xenotransplantation (Supplementary Fig. 7 ). As shown in Supplementary Fig. 14 , the violin plot and heatmap revealed that the gene expression profiles of CD34 + and CD34 − HSCs and MEPs were clearly different. The MEPs expressed higher levels of the NFE2, GFI1B, GATA2, TFRC, MYC and MYB genes than CD34 + and CD34 − HSCs. Interestingly, CD34 − HSCs expressed higher levels of the MYB gene, which regulates the biphenotypic fate of human MEPs 55 , than CD34 + HSCs. It is true that the gene expression profiling solely is not sufficient to argue for the molecular implication in the difference in self-renewal, maintenance and epigenetic regulation of our currently identified HSC subpopulations. We, however, believe that the difference in the gene expression profiling between the HSC subpopulations provides an important clue for elucidating the molecular background sustaining the differential cellular functions of these HSC subpopulations.
Collectively, in vivo, CD34 − HSCs can differentiate in line with our proposed model (Fig. 7b) . They first generate CD34 + HSCs, which then give rise to MPPs, MLPs, CMPs, GMPs and MEPs. In contrast, in methylcellulose cultures, CD34 − HSCs may bypass the stage of CD34 + HSCs and directly differentiate into MEPs. Consistent with this hypothesis, CD34 − HSCs expressed a higher level of gene sets related to megakaryocyte/erythrocyte differentiation (Fig. 6a) and displayed stronger megakaryocyte/erythrocyte differentiation capability even in vivo ( Supplementary  Fig. 8a ). Based on the present studies, we propose a revised megakaryocyte/erythrocyte bypass route as shown in Fig. 7b . However, it remains as a possibility that CD34 − HSCs are able to Fig. 7 The current and proposed models for human HSC hierarchy. a The current model [1] [2] [3] for the human HSC hierarchy. CD34 + HSCs as defined by a CD34 + CD38 − CD45RA − CD90 + CD49f + immunophenotype differentiate into MPPs, CMPs, MLPs, GMPs and MEPs. b The model 19, 20 proposed based on our series of studies 18, 21, 22, 25, [33] [34] [35] [36] 60 , in which CD34 − HSCs are defined by a CD34 − CD38 low/− CD45RA − FLT3 − CD110 − CD133 + GPI-80 + immunophenotype. CD34 − HSCs generate CD34 + HSCs in vitro 25, 35, 36 and in vivo 18, 33 , suggesting that CD34 − HSCs reside at the apex of human HSC hierarchy. CD34 − HSCs, then, differentiate into MPPs, CMPs, GMPs and MEPs according to the current model [1] [2] [3] . Incorporating the present studies, a revised road map, which allows a commitment/differentiation pathway of CD34 − HSCs directly into MEPs (bypass route), is shown. MPP: multipotent progenitor, MLP: multilymphoid progenitor, CMP: common myeloid progenitor, GMP: granulocyte/macrophage progenitor, MEP: megakaryocyte/ erythrocyte progenitor differentiate via CD34 + HSCs in line with our proposed model under influence of the specific niche cells/factors as seen in vivo.
As shown in Supplementary Fig. 15 , we did not detect 18Lin − CD34 − CD133 + GPI-80 + cells in adult BM cells. These results suggest that CD34 − HSCs may be a CB-specific population, while there is a possibility that young adults' or childrens' BMs contain CD34 − HSCs.
In conclusion, our present study has major implications for the precise characterization of the most primitive class of human CD34 − HSCs as well as for HSCT in transplantation medicine. From the viewpoint of HSCT, it is important to develop an efficient method for expanding CB-derived HSCs for transplantation, as CB transplantation (CBT) is now one of the most commonly used sources for allogeneic HSCT worldwide [42] [43] [44] . However, the number of HSCs in CB units is limited, so CBT is often associated with delayed neutrophil and platelet recovery as well as graft failure, which represents a life-threatening complication [42] [43] [44] . In this study, we tried to expand very primitive CBderived CD34 − SRCs (HSCs) (18Lin − CD34 − CD133 + GPI-80 + cells) using SCF, TPO, FL plus StemRegenin-1 (SR-1) 45 or pyrimidoindole derivative (UM171) 46 . However, it was hard to expand CD34 − and CD34 + SRCs (HSCs) under these culture conditions ( Supplementary Fig. 13 ). Further studies will be required to develop an efficient method for HSC ex vivo expansion.
Methods
Collection of CB and bone marrow samples. CB samples were obtained from normal full-term deliveries with written informed consent. Human BM samples were obtained from healthy donor BM remaining in the collection bag after clinical BM transplantation with informed consent. This study was approved by the Institutional Review Board of Kansai Medical University. The CB-and BM-derived lineage-negative (Lin − ) mononuclear cells were separated using an EasySep Human Progenitor Cell Enrichment Kit (StemCell Technologies, Vancouver, BC, Canada) in accordance with the manufacturer's instructions, as previously reported 18, 21, 22, 25, [33] [34] [35] [36] . (Fig. 1a-f) . The purity of sorted cells was always confirmed by a post-sorting purity analysis. In order to define the CD34 − fraction for flow cytometric analyses, the gate was set based on the Fluorescent Minus One (FMO) control.
Immunostaining of Lin
The surface marker expression of purified HSC populations. The expression of CD90, CD49f, CD93 and CD184 (CXCR4) on the surface of 18Lin − CD34 + CD38 − CD133 + GPI-80 + and 18Lin − CD34 − CD133 + GPI-80 + cells was analyzed using FACSCantoII (BD Biosciences). Human CB-derived Lin − cells obtained from individual samples (n = 7) were stained with a mixture of FITC-conjugated 18 Lin mAbs, PE-conjugated anti-GPI-80 mAbs, PE-Cy7-conjugated anti-CD38 mAb, APC-conjugated anti-CD133/1 mAb, APC-Cy7-conjugated anti-CD34 mAb (BioLegend), BV510-conjugated anti-CD45 mAb and biotin-conjugated anti-CD90 (BioLegend), CD49f (BioLegend), CD184 (BioLegend) or CD93 mAb (OriGene). Biotin-conjugated mAbs were then reacted with BV421-conjugated streptavidin for 30 min at 4°C. The samples were washed twice with PBS − /FCS followed by 7-AAD staining before the analysis. The positive gate for the BV421 fluorescence channel was defined according to the FMO control.
Isolation of target cells for single-cell analyses.
In order to analyze the singlecell gene expression profiles, CB-derived single CD34 + HSCs and CD34 − HSCs were isolated by FACSAriaII with the automated cell deposition unit (ACDU). Single CD90 + HSCs, MPPs, multi-lymphoid progenitors (MLPs), CMPs, granulocyte and monocyte progenitors (GMPs), megakaryocyte and erythrocyte progenitors (MEPs), erythroblasts, monocytes/macrophages, megakaryocytes, B cells and T cells were also isolated in accordance with previous reports 2, 3 by FACS. The details of the immunophenotypes of these fractions of cells are described in Supplementary Data 6.
An analysis of the morphology of the highly purified cells. Portions of 18Lin − CD34 + CD38 − CD133 + GPI-80 +/− and 18Lin − CD34 − CD133 + GPI-80 +/− cells were cytospun onto a slide glass. They were then stained with May-GrunwaldGiemsa for morphological analysis. The images of the cells were recorded using an inverted microscope system (BZ-9000, Keyence, Osaka, Japan) with a ×100 Apo oil objective lens (Fig. 1g ). 21, 22, 34, 53 . TPO, GM-CSF, G-CSF, IL-3 and Epo were kindly provided by Kyowa Hakko Kirin Company (Tokyo, Japan). The plates were cultured for 10 to 14 days and then assayed as reported previously 21, 22, 33, 35, 36, 56 . We analyzed various types of colony-forming cells (CFCs), including megakaryocyte-containing CFCs, as reported 21, 22, 33, 35, 36, 56 . We picked up all of the colonies derived from single-cells under an inverted microscope. Cytospin preparations were made using Cytospin (Thermo Fisher Scientific, Waltham, MA, USA) for all colonies picked up from a total of eight 96-well flatbottomed plates. These cytospin preparations were stained with May-GrunwaldGiemsa for a morphological analysis. We identified neutrophils (n), macrophages (m), eosinophils (e), erythroblasts/erythrocytes (E) and megakaryocytes (M) and classified each colony as a single and/or multi-lineage one. Each colony type was classified as follows: colony-forming unit-granulocyte (CFU-G) containing n; colony-forming unit-macrophage (CFU-M) containing m; colony-forming unitgranulocyte/macrophage (CFU-GM) containing nm, ne or nme; colony-forming unit-eosinophil (CFU-Eo) containing e; burst-forming unit-erythroid (BFU-E) containing E; colony-forming unit-megakaryocyte (CFU-Meg) containing M; colony-forming unit-erythrocyte/megakaryocyte (CFU-EM) containing E and M; colony-forming unit-mixed (CFU-Mix) containing nE, nM, mM, nmE, nEM, nmM, neE, neM, nmEM or nmeEM (Supplementary Fig. 2 ).
Single-cell proliferation assay. Single 18Lin -CD34 + CD38 − CD133 + GPI-80 + , 18Lin − CD34 − CD133 + GPI-80 + and 18Lin − CD34 + CD38 high cells were sorted using the ACDU into 60-well MiniTray (Thermo Fisher Scientific) which contained StemPro-34 SFM plus GlutaMax (1:100, Thermo Fisher Scientific) supplemented with a cocktail of 2 cytokines (100 ng/mL TPO and 50 ng/mL SCF: referred to as basal medium), or with 10% FCS (Biosera) added and supplemented with the a cocktail of 7 cytokines (100 ng/mL TPO, 50 ng/mL SCF, 50 ng/mL fms-like tyrosine kinase-3 ligand (FL) [Cell Signaling Technology, Beverly, MA, USA], 20 ng/mL of G-CSF, 10 ng/mL of GM-CSF, 10 ng/mL IL-3 and 10 ng/mL IL-6 [Peprotech, Rocky Hill, NJ, USA]; referred to as complete medium) at 37°C under 5% CO 2 in air. The first and second cell division times were assessed by microscopic observation at 12 h intervals from 30 to 144 h.
Cell cycle analyses. The cell cycle status of the abovementioned CB-derived highly purified HSC populations, such as 18Lin − CD34 + CD38 − CD133 + GPI-80 +/− and 18Lin − CD34 − CD133 + GPI-80 +/− cells were analyzed as mentioned below. As controls, the cell cycle status of CB-and BM-derived CD90 + HSCs, MPPs, MLPs and Lin − CD34 + CD38 high cells was also analyzed. These hematopoietic stem/ progenitor cell (HSPCs) were obtained by FACS as follows; cryopreserved CB and BM samples were thawed and Lin − cells were immediately separated using an EasySep Human Progenitor Cell Enrichment Kit as described above. Immunomagnetically enriched Lin − cells were stained with surface markers by a cocktail of fluorochrome-conjugated mAbs as shown in Supplementary Data 5. Intracellular staining was then carried out using a BD Cytofix/Cytoperm Kit (BD Bioscience) in accordance with the manufacturer's instruction. The cells were fixed with Cytofix/ Cytoperm buffer (BD Bioscience) for 10 min at 4°C. Subsequently, the cells were placed into PermWash buffer (BD Bioscience) and then reacted with PE-Cy7-conjugated anti-human Ki-67 mAb (1:25, BioLegend) and 7-AAD (1:50) at 4°C for overnight. The expressions of surface markers and Ki-67 antigens and the DNA content in each fraction of cells were analyzed by an eight-color FCM (FACSCanto II). G 0 , G 1 and S/G 2 /M gates were defined according to the FMO control.
NOG and NSG mice. Female six-week-old NOD.Cg-Prkdc scid Il2rg tm1Sug /Jic (NOG) 57 and NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NSG) 58 mice were purchased from the Central Institute of Experimental Animals (Kawasaki, Japan) and Charles River Laboratories Japan, Inc. (Yokohama, Japan), respectively. All mice were handled under sterile conditions and maintained in germ-free isolators in the Central Laboratory Animal Facilities of Kansai Medical University. In order to reduce the oxidative stress, mice were given feed containing 1.3% N-acetyl-Lcysteine (NAC) for the entire repopulation period, as previously reported 59 . The animal experiments were approved by the Animal Care Committees of Kansai Medical University. NOG and NSG mice (8-week-old) were sub-lethally irradiated (2.5 Gy using a 137 Cs-γ irradiator) immediately before all of the transplantation studies.
Intra-BM injection of purified cells. IBMI was carried out as reported previously 18, 21, 22, 25, [33] [34] [35] [36] 60 . Briefly, after sterilization of the skin around the left knee joint, the knee was flexed to 90 degrees and the proximal side of the tibia was drawn to the anterior. A 26-gauge needle was inserted into the joint surface of the tibia through the patellar tendon and then inserted into the BM cavity. Using a Hamilton microsyringe, the specified number of cells per 10 μL of α-medium plus 5% FCS were carefully injected from the bone hole into the BM cavity.
SCID-repopulating cell assay by FCM. The SRC assays were performed by the previously reported method 18, 21, 22, 25, [34] [35] [36] 60 . In this study, a specified number of 18Lin − CD34 + CD38 − CD133 + GPI-80 +/− and 18Lin − CD34 − CD133 + GPI-80 +/− cells were transplanted by IBMI into eight-week-old NOG or NSG mice. Human hematopoietic repopulations in the mouse BMs were serially analyzed 12 and 18 weeks after transplantation by the BM aspiration method 18, 21, 22, 25, [34] [35] [36] 60 . The aliquots of BM aspirates were stained with a Pacific Blue (PB)-conjugated antihuman CD45 mAb (BioLegend), a PE-Cy7-conjugated anti-mouse CD45.1 mAb (Beckman Coulter), FITC-conjugated anti-human CD19 mAb, PE-conjugated antihuman CD33 mAb (Beckman Coulter), APC-conjugated anti-human CD34 mAb (BD Biosciences) and 7-AAD and were analyzed by six-color FCM (FACS CantoII). At weeks 20 to 22, the mice were killed, and the BM cells were collected by crushing the femurs and tibiae from each of mice in a mortar. The cells from the PB, spleen (SP) and thymus (Thy) of these mice were also collected. The repopulation of human hematopoietic cells in the murine BM, PB, SP and Thy were determined by detecting the number of 7-AAD − cells positively stained with PBconjugated anti-human CD45 mAb by six-color FCM (FACS CantoII). The cells were also stained with a PE-Cy7-conjugated anti-mouse CD45.1 mAb (Beckman Coulter); FITC-or BV510-conjugated anti-human CD3 (BM, Thy), CD19 (BM, PB, SP), CD11b (BM) and CD235a (BM) mAbs; PE-conjugated anti-human CD4 (Thy) (eBioscience), CD33 (BM, PB, SP), CD14 (BM) and CD41 (BM, SP) mAbs (Beckman Coulter), and APC-conjugated anti-human CD8 (Thy) (eBioscience) and CD34 (BM, PB, SP) mAbs (BD Biosciences) for the detection of human stem/ progenitor, B-lymphoid, T-lymphoid and myeloid/monocytic hematopoietic cells. For the precise analysis of the NK-cell development in the spleen, the cells were stained with an FITC-conjugated anti-human CD56 mAb (BD Biosciences). In order to determine the human CD45 + gate for the transplantation analyses, BM tissue from NSG mice that did not receive human cells was used as a negative control and human cord blood-derived mononuclear cells were used as a positive control. In all transplantation experiments, the mice were scored as positive if more than 0.01% of the total murine BM cells were human CD45 + cells, as previously reported 22 .
Secondary transplantation. For secondary transplantations, murine BM cells were obtained 19 to 23 weeks after the transplantation from pairs of the femurs and tibiae from engrafted primary recipient NOG/NSG mice receiving the abovementioned purified 18Lin − CD34 + CD38 − CD133 + GPI-80 + and 18Lin − CD34 − CD133 + GPI-80 + cells. The secondary transplantation was then performed, as previously reported 18, 21, 22, 33, 36 . Briefly, 1/5 of the whole BM cells were transplanted into both tibiae of secondary recipient mice by IBMI. Some of the whole BM cells were stained with the FITC-conjugated 18 Lin mAbs, BV510-conjugated anti-CD45 mAb, BV421-conjugated anti-CD34 mAb, PE-Cy7-conjugated anti-CD38 mAb, APC-conjugated anti-CD133/1 mAb and PE-conjugated anti-GPI-80 mAb. The 18Lin − CD34 + and 18Lin − CD34 − cells were then resorted and transplanted into secondary recipient mice. Expression of CD38, CD133 and GPI-80 on these 18Lin − CD34 +/− cells recovered from the engrafted primary recipient mice was analyzed by FCM. Finally, at 19 to 23 weeks after transplantation, presence of human CD45 + cells in the secondary recipients' BMs was analyzed by FCM, as described above.
In vivo limiting dilution analysis. To assess frequency of SRCs in CB-derived 18Lin − CD34 + CD38 − CD133 + GPI-80 +/− and 18Lin − CD34 − CD133 + GPI-80 +/− cells, various numbers of cells, the precise numbers of which are shown in Supplementary Data 1, were transplanted into NSG mice by IBMI, as previously reported 18, 21, 22, 25, 33 . The human cell repopulation in the mouse BM was analyzed at 20 weeks after transplantation by FCM.
Single-cell transplantation. Single 18Lin − CD34 + CD38 − CD133 + GPI-80 + or 18Lin − CD34 − CD133 + GPI-80 + cells were sorted into a 60-well MiniTray in 20 μL of α-medium with 10% FCS using the ACDU with a FACSAriaII. After sorting, the cells were incubated in the CO 2 incubator for 1 h, and visualized under an inverted microscope. Each cell was transferred into a Hamilton microsyringe under the inverted microscope. Wells were re-visualized to confirm that the cell had been successfully transferred into the syringe. In another independent experiment, we confirmed the viability (>99%) of single-sorted cells by Trypan blue dye exclusion. We next analyzed efficiency of our single-cell transplantation method. We sorted single 18Lin − CD34 + CD38 − CD133 + GPI-80 + or 18Lin − CD34 − CD133 + GPI-80 + cells into a 60-well MiniTray. After transferring the cells into a Hamilton microsyringe, the cells were expunged into a new 60-well MiniTray and spun down and visualized. We observed a single cell in 87% of the wells (n = 117), indicating that only 87% of recipient mice transplanted with single 18Lin − CD34 + CD38 − CD133 + GPI-80 + or 18Lin − CD34 − CD133 + GPI-80 + cells actually received a single cell. This efficiency was taken into consideration in our evaluation of the single-cell transplantation data of LDA.
Single-cell initiated serial transplantation. We performed secondary transplantations from primary engrafted recipient mice that received single purified 18Lin − CD34 + CD38 − CD133 + GPI-80 + and 18Lin − CD34 − CD133 + GPI-80 + cells at 21 to 23 weeks after transplantation. In these cases, we transplanted 2/5 of the whole BM cells into both tibiae of two secondary recipient mice by IBMI. Tertiary transplantation was performed in the same way as secondary transplantations; we transplanted 2/5 of the whole BM cells obtained from secondary recipient mice into both tibiae of two tertiary recipient mice by IBMI. The human CD45 + cell repopulation in the secondary and tertiary recipient mice was analyzed at 12 weeks after the transplantation by the BM aspiration technique. At 21 to 23 weeks after transplantation, the mice were killed and the BM cells were collected by crushing the femurs and tibiae from each of the mice in a mortar. The cells from the PB, SP and Thy of these mice were also collected. The repopulation of human hematopoietic cells in the murine BM, PB, SP and Thy were determined by detecting the number of 7-AAD − cells positively stained with PB-conjugated anti-human CD45 mAb by six-color FCM (FACS CantoII). The cells were also stained with a PE-Cy7-conjugated anti-mouse CD45.1 mAb (Beckman Coulter); FITC-or BV510-conjugated anti-human CD3 (BM, Thy), CD19 (BM, PB, SP), CD11b (BM) and CD235a (BM) mAbs; PE-conjugated anti-human CD4 (Thy) (eBioscience), CD33 (BM, PB, SP), CD14 (BM) and CD41 (BM) mAbs (Beckman Coulter), and APCconjugated anti-human CD8 (Thy) (eBioscience) and CD34 (BM, PB, SP) mAbs (BD Biosciences) for the detection of human stem/progenitor, B-lymphoid, Tlymphoid and myeloid/monocytic hematopoietic cells. For the precise analysis of the NK-cell development in the spleen, the cells were stained with an FITC-conjugated anti-human CD56 mAb (BD Biosciences).
Real-time reverse transcription polymerase chain reaction. The primers were designed using the NCBI/Primer BLAST (http://www.ncbi.nlm.nih.gov/tools/ primer-blast/) and Primer3 web tool (http://primer3.ut.ee/). The primer pairs used for RT-PCR are shown in Supplementary Data 7. The primer melting temperature (Tm) of all primers was set at 59 to 63°C. We designed both the first (for preamplification) and second (for real-time PCR) primer pairs for individual target genes. Both the forward and reverse second primers were designed to slide at least three bases inside of the amplicon produced by the first primer pairs.
To validate the gene amplification by each primer pair, total RNA was extracted from CB-derived mononuclear cells using an RNeasy Plus Micro kit (QIAGEN, Hilden, Germany). Reverse transcription was then carried out using an iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA) as follows: 5 min at 25°C, 30 min at 42°C and 5 min at 85°C. The cDNA was then mixed with Power SYBR green Master Mix (Thermo Fisher Scientific), and real-time PCR were then carried out by Rotor-Gene Q (QIAGEN). PCR amplicons were subjected to gel electrophoresis, and the size of the PCR amplicon was validated by comparison with the predicted product size, which was calculated using NCBI/Primer BLAST and Primer3 web tools.
To compare the expression of the VNN2 gene between 18Lin − CD34 + CD38 − CD133 + GPI-80 +/− and 18Lin − CD34 − CD133 + GPI-80 +/− cells, total RNA was extracted from 1.4 × 10 4 of each fraction of cells. As positive and negative controls, 1.4 × 10 4 cells of CB-derived neutrophils and THP-1 cells were used. Reverse transcriptions and real-time PCR were then carried out as described above. The primer sequences for the VNN2 genes were as follows: forward primer (5'-TGGA CGGCCAGTAGAAACTGC-3′), reverse primer (5′-ACCAAACGCCCATCTTT CAGC-3′). The expression of VNN2 was normalized by that of ACTB (β-actin) in each sample. The relative gene expression was calculated by using the 2 -ΔΔC T method. All primers were purchased from Thermo Fisher Scientific.
Cell line. THP-1 cell line was purchased from RIKEN BRC CELL BANK (Tsukuba, Japan).
